RecruitingPrimary Membranous Nephropathy
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Eligible age
18–80 yrs
Accepts
All genders
Locations
19 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Sponsor: Vertex Pharmaceuticals Incorporated
Where it's recruiting
Source: ClinicalTrials.gov · NCT07204275 · last updated 2026-11-18